Zevra Therapeutics to Participate at Upcoming Investor Conferences
Zevra Therapeutics (NASDAQ: ZVRA) has announced its participation in two major investor conferences in December 2024. President and CEO Neil F. McFarlane will present at the Piper Sandler 36th Annual Healthcare Conference on December 4 at 10:30 a.m. ET, and the Oppenheimer Movers in Rare Disease Summit on December 12 at 2:45 p.m. ET.
Management will be available for one-on-one meetings with registered attendees at both events. The Piper Sandler fireside chat will be available via webcast through the company's investor relations website.
Zevra Therapeutics (NASDAQ: ZVRA) ha annunciato la sua partecipazione a due importanti conferenze per investitori a dicembre 2024. Il Presidente e CEO Neil F. McFarlane presenterà alla 36ª Conferenza Sanitaria Annuale di Piper Sandler il 4 dicembre alle 10:30 a.m. ET, e al Vertice Oppenheimer Movers in Rare Disease il 12 dicembre alle 2:45 p.m. ET.
Il management sarà disponibile per incontri individuali con i partecipanti registrati ad entrambi gli eventi. La conversazione a fuoco di Piper Sandler sarà disponibile in streaming sul sito web delle relazioni con gli investitori dell'azienda.
Zevra Therapeutics (NASDAQ: ZVRA) ha anunciado su participación en dos importantes conferencias para inversores en diciembre de 2024. El Presidente y CEO Neil F. McFarlane presentará en la 36ª Conferencia Anual de Salud de Piper Sandler el 4 de diciembre a las 10:30 a.m. ET, y en la Cumbre Oppenheimer Movers en Enfermedades Raras el 12 de diciembre a las 2:45 p.m. ET.
La dirección estará disponible para reuniones uno a uno con los asistentes registrados en ambos eventos. La charla de Piper Sandler estará disponible a través de transmisión web en el sitio de relaciones con inversores de la empresa.
제브라 테라퓨틱스 (NASDAQ: ZVRA)는 2024년 12월에 열리는 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 사장 겸 CEO인 닐 F. 맥팔레인이 12월 4일 오전 10시 30분 ET에 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스에서 발표하며, 12월 12일 오후 2시 45분 ET에 옵페나이머 희귀 질환 정상 회담에서 발표할 예정입니다.
경영진은 두 행사에서 등록된 참가자와의 일대일 미팅을 위해 대기할 것입니다. 파이퍼 샌들러의 대화는 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 제공될 예정입니다.
Zevra Therapeutics (NASDAQ: ZVRA) a annoncé sa participation à deux grandes conférences pour investisseurs en décembre 2024. Le Président et CEO Neil F. McFarlane présentera à la 36e Conférence Annuelle de Santé de Piper Sandler le 4 décembre à 10h30 ET, et au Sommet Oppenheimer Movers dans les Maladies Rares le 12 décembre à 14h45 ET.
La direction sera disponible pour des réunions individuelles avec les participants enregistrés lors des deux événements. La discussion de Piper Sandler sera accessible par webcast via le site de relations investisseurs de l'entreprise.
Zevra Therapeutics (NASDAQ: ZVRA) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember 2024 bekannt gegeben. Präsident und CEO Neil F. McFarlane wird am 4. Dezember um 10:30 Uhr ET auf der 36. jährlichen Healthcare-Konferenz von Piper Sandler und am 12. Dezember um 14:45 Uhr ET beim Oppenheimer Movers in Rare Disease-Gipfel präsentieren.
Die Geschäftsführung wird beiden Veranstaltungen für Einzelgespräche mit registrierten Teilnehmern zur Verfügung stehen. Der Piper Sandler Fireside Chat wird über die Website der Investor Relations des Unternehmens als Webcast verfügbar sein.
- None.
- None.
CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in the following December investor events.
- Piper Sandler 36th Annual Healthcare Conference, on Wednesday, December 4, 2024, at 10:30 a.m. ET.
- Oppenheimer Movers in Rare Disease Summit Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts, on Thursday, December 12, 2024, at 2:45 p.m. ET as part of an invitation-only event hosted by Oppenheimer.
Additionally, management will be available for one-on-one meetings with registered attendees at each conference. The live webcast of the Piper Sandler fireside chat will be accessible via “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly Report for the quarter ended Sept. 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Russo Partners Contact
David Schull
+1 (858) 717-2310
david.schull@russopartnersllc.com
FAQ
When is Zevra Therapeutics (ZVRA) presenting at the Piper Sandler Healthcare Conference 2024?
What investor conferences is Zevra Therapeutics (ZVRA) attending in December 2024?
How can investors watch Zevra Therapeutics' (ZVRA) Piper Sandler presentation?
When is Zevra Therapeutics (ZVRA) presenting at the Oppenheimer Rare Disease Summit 2024?
